Search

Search Results

• NK-Cell Receptor Repertoire in Chronic Myeloid Leukemia

  Tamara Vangelevna Chitanava, R.A. Vlasik, L.O. Khordzhasov, A. Ataman, N.S. Luchkina, A.Yu. Aronov, I.D. Matvienko, N.T. Siordiya, O.V. Kulemina, N.S. Lazorko, E.I. Sbityakova, N.A. Shnalieva, E.N. Tochenaya, J.A. Alekseeva, P.A. Butylin, S.V. Smirnov, Yu. A. Zaritskii, Yu.P. Martinova, E.G. Lomaia

  152-161

  01.04.2026

• Level and Serum Metabolism of Homocysteine in Chronic Myeloid Leukemia Patients: A Literature Review

  K.S. Samarina, Yuliana Yurevna Assesorova, I.V. Berger

  162-171

  01.04.2026

• Phase 3 Clinical Trial of 300 mg Vamotinib Directly Compared with High-Dose Imatinib in Chronic Myeloid Leukemia Patients in Chronic Phase with Failure of Standard-Dose Imatinib: Interim Analysis

  A.G. Turkina, O. Yu. Vinogradova, E.G. Lomaia, B.A. Bakirov, N.M. Kalimulina, T.V. Shelekhova, I.L. Davydkin, T.I. Pospelova, O.A. Shukhov, E.Yu. Chelysheva, V.A. Shuvaev, S. Lavana, V. Khushoo, S. Apte, T.K. Dolai, R.K. Sahoo, Germes Grigorevich Chilov

  1-13

  01.01.2026

• The Role of Somatic Mutations in Various Genes and the Issue of Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients: A Literature Review

  Elena Andreevna Kuzmina, E.Yu. Chelysheva, B.V. Biderman, A.G. Turkina

  10-20

  01.01.2025

• Interim Results of the Russian Prospective Multi-Center Clinical Trial READIT-2020 (Reduction of Tyrosine Kinase Inhibitor Doses in CML Patients, Plasma Imatinib/Nilotinib Concentrations, Sustaining Molecular Response, and Drug Toxicity)

  Margarita Anatolevna Gurianova, V.I. Kazey, O.A. Shukhov, E.Yu. Chelysheva, A.G. Nikiforova, P.D. Sobolev, M.S. Dolov, D.Yu. Grebenkin, A.N. Petrova, A.V. Bykova, I.S. Nemchenko, E.A. Kuzmina, L.V. Gavrilova, A.V. Kokhno, A.G. Turkina

  347-359

  01.10.2024

• Treatment Outcomes with Asciminib, the First Allosteric BCR::ABL1 Tyrosine Kinase Inhibitor, in Chronic Myeloid Leukemia Patients with Multiple Resistance to Prior Therapy

  A.G. Turkina, Elena Andreevna Kuzmina

  311-320

  09.06.2023

• KIR-Genetic Factors and Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

  Elena Vital’evna Kuzmich, I.E. Pavlova, L.N. Bubnova, S.S. Bessmeltsev

  119-127

  03.03.2023

• Asciminib in Chronic Myeloid Leukemia Patients Without Therapeutic Alternatives: Results of the MAP (Managed Access Program, NCT04360005) Trial in Russia

  A.G. Turkina, Elena Andreevna Kuzmina, E.G. Lomaia, E.V. Morozova, E.Yu. Chelysheva, O.A. Shukhov, A.N. Petrova, T.V. Chitanava, Yu.Yu. Vlasova, I.S. Nemchenko, A.V. Bykova, E.I. Sbityakova, M.A. Gurianova, N.N. Tsyba, A.V. Kokhno, E.N. Parovichnikova

  54-68

  01.01.2023

• Efficacy Predictors of the Third-Line Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase of Chronic Myeloid Leukemia: Results of a Multi-Center Study

  E.G. Lomaia, V.A. Shuvaev, Tamara Vangelevna Chitanava, Yu.D. Matvienko, I.S. Martynkevich, S.V. Voloshin, E.V. Efremova, E.S. Mileeva, M.S. Fominykh, A.E. Kersilova, E.V. Karyagina, N.V. Il’ina, N.V. Dorofeeva, N.V. Medvedeva, A.V. Klimovich, T.V. Shneider, S.A. Stepanova, N.F. Polezhaikovskaya, N.T. Siordiya, E.I. Sbityakova, N.S. Lazorko, E.N. Tochenaya, D.V. Motorin, N.A. Shnalieva, Yu.A. Alekseeva, D.B. Zammoeva, A.Yu. Zaritskey

  271-281

  01.07.2022

• Russian Prospective Non-Randomized Clinical Study on Dose Reduction of Tyrosine Kinase Inhibitors with Subsequent Complete Therapy Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response (READIT-2020): Background, Aim, Mai

  A.G. Turkina, Margarita Anatolevna Gurianova, E.Yu. Chelysheva, O.A. Shukhov

  54-61

  01.01.2022

• Biological Mechanisms of Sustaining Deep Molecular Response in Chronic Myeloid Leukemia Upon Withdrawal of Tyrosine Kinase Inhibitors

  Ekaterina Yurevna Chelysheva, M.A. Guryanova, A.G. Turkina

  427-435

  01.10.2021

• Treatment of Mastocytosis: A Literature Review

  Karina Maksimovna Chernavina, A.S. Orlova, E.A. Nikitin

  361-369

  01.07.2021

• Opportunities of Chronic Myeloid Leukemia Treatment with Reduced Doses of Tyrosine Kinase Inhibitors

  Margarita Anatolevna Guryanova, E.Yu. Chelysheva, A.G. Turkina

  118-128

  01.01.2021

• Factors for Sustaining Molecular Remission after Discontinuation of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia: Results of Non-Randomized Prospective Clinical Trial

  Oleg Aleksandrovich Shukhov, A.N. Petrova, E.Yu. Chelysheva, A.V. Bykova, I.S. Nemchenko, A.G. Turkina

  1-12

  01.01.2021

• Chronic Myeloid Leukemia: Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Tyrosine Kinase Inhibitors

  Elena Vladislavovna Morozova, Yu.Yu. Vlasova, M.V. Barabanshchikova, N.N. Mamaev, I.M. Barkhatov, A.L. Alyanskii, E.I. Darskaya, M.V. Vladovskaya, S.N. Bondarenko, I.S. Moiseev, B.V. Afanasyev

  193-198

  01.04.2020

• Comparative Analysis of Cardiovascular Disorders in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitor Therapy

  L.M. Makeeva, E.I. Emelina, A.V. Bykova, Gennadii Efimovich Gendlin, G.A. Gusarova, I.G. Nikitin, E.Yu. Chelysheva, O.Yu. Vinogradova, I.E. Lazarev, E.G. Arshanskaya, A.G. Turkina

  104-111

  01.01.2020

• Management of Chronic Myeloid Leukemia Patients During Pregnancy (Analysis of Literature and Practical Recommendations)

  Ekaterina Yur’evna Chelysheva, A.G. Turkina, E.S. Polushkina, M.A. Vinogradova, R.G. Shmakov

  202-210

  01.04.2019

• Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ)

  Oleg Aleksandrovich Shukhov, A.G. Turkina, E.Yu. Chelysheva, A.V. Bykova, A.N. Petrova, G.A. Gusarova, I.S. Nemchenko, A.O. Abdullaev, T.N. Obukhova, A.B. Sudarikov

  194-201

  01.04.2019

• Clinical Experience and Perspectives of Bosutinib Use in Patients with Chronic Myeloid Leukemia

  V.A. Shuvaev, Ol’ga Yur’evna Vinogradova, I.S. Martynkevich, N.V. Novitskaya, M.S. Fominykh, S.N. Tsareva, D.I. Shikhbabaeva, M.M. Pankrashkina, M.V. Chernikov, N.N. Sharkunov, I.I. Zotova, V.Yu. Udal’eva, E.V. Motyko, S.V. Voloshin

  288-294

  01.10.2018

• Cardiovascular Toxicity of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

  I.L. Davydkin, Kseniya Viktorovna Naumova, A.M. Osadchuk, I.A. Zolotovskaya, O.E. Danilova, T.Yu. Stepanova, O.V. Tereshina, L.V. Limareva, A.S. Shpigel’, T.P. Kuz’mina

  378-387

  01.10.2018

• Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice

  Anna Grigor’evna Turkina, N.V. Novitskaya, A.K. Golenkov, V.A. Shuvaev, L.I. Napso, I.V. Krylova, A.M. Savrilova, G.Sh. Safuanova, A.V. Korobkin, T.Yu. Klitochenko, E.V. Burnasheva, E.V. Vasil’ev, O.M. Senderova, E.Yu. Fedorova, L.M. Yalunina, E.K. Nekhai, G.B. Kuchma, A.S. Lyamkina, N.G. Shchedrova

  390-401

  01.07.2017

• Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors

  Galina Anatol’evna Gusarova, A.G. Turkina

  474-484

  01.10.2016

• Mixed-Phenotype Acute Leukemia: Clinical and Laboratory Features, and Prognosis

  A.S. Antipova, Ol’ga Yur’evna Baranova, M.A. Frenkel’, N.N. Tupitsyn, N.A. Kupryshina, T.N. Obukhova, A.D. Shirin

  136-150

  01.04.2015

• Current best options for first line treatment of chronic phase chronic myeloid leukemia

  R. Hehlmann, S. Saußele

  9-15

  01.01.2014